Lequembi was approved with CDR-SB as primary endpoints and ADAS-Cog 14 and ADCS-MCI-ADL these scales are better than -Cog13 and ADCDS-ADL for a population that was almost entirely MCI.
Donanemab was approved using the iADRS scale (Which is a combination of ADAS-Cog 13 and ADCS-iADL).
Market Data 
Markets 
AI
